Blinatumomab Plus Chemotherapy New Standard for Children With B-Cell ALL

(MedPage Today) -- The randomized phase III AALL1731 trial presented at the American Society of Hematology annual meeting showed that adding the bispecific T-cell engager blinatumomab (Blincyto) to chemotherapy significantly improved disease-free...